Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.46 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.43 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.43 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | EYA2 | O00167 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL17747958 | 1.00 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL23854440 | 0.97 | KDM4E (0.74) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL10607814 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL1714086 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL991956 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL978169 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL8374505 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL7071979 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL8470881 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL506851 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206231-A1 | TOPICAL PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMA | BIOLAB SANUS FARMACEUTICA LTDA (BR) | 2020-07-02 | — | — | US | claimed |
| EP-2839833-B1 | TOPICAL PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF THE TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMA | BIOLAB SANUS FARMACEUTICA LTDA (BR) | 2018-06-13 | — | — | EP | claimed |
| US-20150079175-A1 | Topical Pharmaceutical Composition, Method for Producing the Topical Pharmaceutical Composition, Use of the Topical Pharmaceutical Composition and Method for the Topical Treatment of Psoriasis, Atopic Dermatitis or Chronic Eczema | BIOLAB SANUS FARMACEUTICA LTDA (BR) | 2015-03-19 | — | — | US | claimed |
| EP-2839833-A1 | TOPICAL PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF THE TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMA | Biolab Sanus Farmacêutica Ltda. (BR) | 2015-02-25 | — | — | EP | claimed |
| EP-4630524-A1 | HYDROTROPE CLEANING COMPOSITIONS | Dow Global Technologies LLC (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4547806-A1 | CLEANING COMPOSITION FOR RECYCLING OF PLASTICS | Dow Global Technologies LLC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240409714-A1 | GLYCOL COMPOSITIONS COMPRISING CHELANTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4430152-A1 | GLYCOL COMPOSITIONS COMPRISING CHELANTS | Dow Global Technologies LLC (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024119291-A1 | HYDROTROPE CLEANING COMPOSITIONS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024020169-A1 | CLEANING COMPOSITION FOR RECYCLING OF PLASTICS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023086546-A1 | GLYCOL COMPOSITIONS COMPRISING CHELANTS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-114159432-A | Ticarcillin sodium and potassium clavulanate pharmaceutical composition and preparation method thereof | 成都倍特药业股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-8404752-B2 | Method of treating traumatic brain injury | OXYGEN BIOTHERAPEUTICS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2341084-A1 | Redispersible polymer powders stabilized with protective colloid compositions | DOW Chemical Company (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20100178347-A1 | Method of treating traumatic brain injury | TENAX THERAPEUTICS, INC | 2010-07-15 | — | — | US | disclosed |
| US-20100144597-A1 | Novel combinatorial approaches to enhancing oxygen transport to tissues | VIRGINIA COMMONWEALTH UNIVERSITY | 2010-06-10 | — | — | US | disclosed |
| EP-0938258-A4 | EMULSIONS OF PERFLUORO COMPOUNDS AS SOLVENTS FOR NITRIC OXIDE (NO) | UNIV TEXAS (US) | 2000-01-19 | — | — | EP | disclosed |
| EP-0938258-A1 | EMULSIONS OF PERFLUORO COMPOUNDS AS SOLVENTS FOR NITRIC OXIDE (NO) | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1997038579-A1 | EMULSIONS OF PERFLUORO COMPOUNDS AS SOLVENTS FOR NITRIC OXIDE (NO) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-10-23 | — | — | WO | disclosed |
| US-4433000-A | WITH PROPYLENE GLYCOL ALGINATE AND SODIUM CARBOXYMETHYL CELLULOSE | COCA COLA COMPANY (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206231-A1 | TOPICAL PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMA | MTX1, MTX2, IL17A | ACE 1001/4885CHRM2 649/4885ADRA2A 2343/4885 |
| US-20150079175-A1 | Topical Pharmaceutical Composition, Method for Producing the Topical Pharmaceutical Composition, Use of the Topical Pharmaceutical Composition and Method for the Topical Treatment of Psoriasis, Atopic Dermatitis or Chronic Eczema | MTX1, FHIT, MTX2 | ACE 1081/4885CHRM2 538/4885ADRA2A 1878/4885 |
| US-20100144597-A1 | Novel combinatorial approaches to enhancing oxygen transport to tissues | SLC2A4, SLC2A1, SLC2A2 | ACE 4727/4885CHRM2 1451/4885ADRA2A 861/4885 |
| US-20100178347-A1 | Method of treating traumatic brain injury | FABP7, PMP22, NEFM | ACE 3052/4885CHRM2 2461/4885ADRA2A 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.